Scholarlink

Objectives <p>Benign prostatic hyperplasia (BPH) is a widespread urological clinical case in aged men associated with troublesome lower urinary tract symptoms and cardiac dysfunction, but its medical treatment is still insufficient. Thus, searching for more effective medical regimens is an essential target. We tried in current experiment to explore the role of bosentan (BOS) and/or finerenone (FIN) in this lesion.</p> Methods <p>BPH was adequately induced using testosterone propionate (TP) in a dose of (5&#xa0;mg/kg/day) for 28 days of subcutaneous injection and an oral administration of BOS (50&#xa0;mg/kg/day) and/or FIN (10&#xa0;mg/kg/day) for 10 days.</p> Results <p>We found typical histopathological changes of BPH, increased serum dihydrotestosterone (DHT), prostatic specific antigen (PSA), cardiac enzymes, tissue malondialdehyde (MDA), aldosterone, endothelin-A, nuclear factor kappa b (NF-κB), and proliferating cell nuclear antigen (PCNA). However, significant decreases in total antioxidant capacity (TAC), reduced glutathione (GSH), and caspase-3. The histological findings were augmented by special staining techniques, immunohistochemical and morphometric studies. There are histopathological alternations as the hyperplastic nodules in the prostate’s transition zone expand, and the prostatic urethra was compressed, lengthened and distorted. Interestingly the co-administration of BOS and/or FIN significantly improved BPH induced changes. This is mostly attributed to its ability in modulating endothelin receptors by BOS, aldosterone receptors by FIN, improved the histopathological changes with anti-oxidant, anti-inflammatory, anti-fibrotic, antiproliferative, and apoptotic properties.</p> Conclusions <p>BOS and/or FIN showed a significant ameliorative effect in BPH.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The interplay of bosentan and finerenone in amelioration of cardiac dysfunction within benign prostatic hyperplasia in rats

  • 期刊论文

  • 发表日期：

    2026年6月30日

查看全文
  • Marwa Monier Mahmoud Refaie,
  • Asmaa A. Hasan,
  • Asmaa A. Muhammed,
  • Randa Ahmed Ibrahim,
  • Eman Abdel Naby Hassan,
  • Enas Fathy,
  • Aml Mohamed Soliman,
  • Hoda S. Sherkawy,
  • Olivia N. Beshay,
  • Amr Alam-Eldin Ahmed,
  • Ahmed Ahmed,
  • Samar Hisham Elsayed,
  • Heba A. Habib

摘要

Objectives

Benign prostatic hyperplasia (BPH) is a widespread urological clinical case in aged men associated with troublesome lower urinary tract symptoms and cardiac dysfunction, but its medical treatment is still insufficient. Thus, searching for more effective medical regimens is an essential target. We tried in current experiment to explore the role of bosentan (BOS) and/or finerenone (FIN) in this lesion.

Methods

BPH was adequately induced using testosterone propionate (TP) in a dose of (5 mg/kg/day) for 28 days of subcutaneous injection and an oral administration of BOS (50 mg/kg/day) and/or FIN (10 mg/kg/day) for 10 days.

Results

We found typical histopathological changes of BPH, increased serum dihydrotestosterone (DHT), prostatic specific antigen (PSA), cardiac enzymes, tissue malondialdehyde (MDA), aldosterone, endothelin-A, nuclear factor kappa b (NF-κB), and proliferating cell nuclear antigen (PCNA). However, significant decreases in total antioxidant capacity (TAC), reduced glutathione (GSH), and caspase-3. The histological findings were augmented by special staining techniques, immunohistochemical and morphometric studies. There are histopathological alternations as the hyperplastic nodules in the prostate’s transition zone expand, and the prostatic urethra was compressed, lengthened and distorted. Interestingly the co-administration of BOS and/or FIN significantly improved BPH induced changes. This is mostly attributed to its ability in modulating endothelin receptors by BOS, aldosterone receptors by FIN, improved the histopathological changes with anti-oxidant, anti-inflammatory, anti-fibrotic, antiproliferative, and apoptotic properties.

Conclusions

BOS and/or FIN showed a significant ameliorative effect in BPH.